BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10636462)

  • 1. ATIII-independence of anticoagulant effect of human urinary soluble thrombomodulin.
    Imada K; Takahashi Y; Hosaka Y; Adachi T; Niina H; Mochizuki H
    Blood Coagul Fibrinolysis; 1999 Dec; 10(8):503-11. PubMed ID: 10636462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III.
    Aoki Y; Ohishi R; Takei R; Matsuzaki O; Mohri M; Saitoh K; Gomi K; Sugihara T; Kiyota T; Yamamoto S
    Thromb Haemost; 1994 Apr; 71(4):452-5. PubMed ID: 8052962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased anticoagulant activity of recombinant thrombomodulin modified with glycosaminoglycan.
    Edano T; Inoue K; Yoshizaki H; Yamamoto S; Komine N; Tabunoki H; Sawada H; Koshi T; Murakami A; Wada Y; Ohkuchi M
    Biol Pharm Bull; 1998 Apr; 21(4):375-81. PubMed ID: 9586576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Species specificity of the anticoagulant activity of human urinary soluble thrombomodulin.
    Takahashi Y; Hosaka Y; Imada K; Adachi T; Niina H; Mochizuki H
    Thromb Res; 1998 Feb; 89(4):187-97. PubMed ID: 9651146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits.
    Tazawa S; Ichikawa K; Misawa K; Fukuyama J; Hamano S; Miyata H; Sakuragawa N
    Thromb Res; 1995 Dec; 80(5):391-8. PubMed ID: 8588200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin.
    Takahashi Y; Hosaka Y; Imada K; Adachi T; Niina H; Watanabe M; Mochizuki H
    Thromb Haemost; 1997 Apr; 77(4):789-95. PubMed ID: 9134660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of human urinary thrombomodulin on endotoxin-induced intravascular coagulation and pulmonary vascular injury in rats.
    Uchiba M; Okajima K; Murakami K; Johno M; Okabe H; Takatsuki K
    Am J Hematol; 1997 Feb; 54(2):118-23. PubMed ID: 9034285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effect of antithrombin III, activated protein C and heparin on the inhibition of the tissue thromboplastin-mediated coagulation.
    Hirahara K; Etoh Y; Matsuishi T; Suzuki N; Kurata M
    Chem Pharm Bull (Tokyo); 1989 Mar; 37(3):692-6. PubMed ID: 2752479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble thrombomodulin purified from human urine exhibits a potent anticoagulant effect in vitro and in vivo.
    Takahashi Y; Hosaka Y; Niina H; Nagasawa K; Naotsuka M; Sakai K; Uemura A
    Thromb Haemost; 1995 May; 73(5):805-11. PubMed ID: 7482407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous extended infusion of recombinant human soluble thrombomodulin prevented tissue factor-induced disseminated intravascular coagulation in rats.
    Mohri M; Oka M; Aoki Y; Gonda Y; Hirata S; Gomi K; Kiyota T; Sugihara T; Yamamoto S; Ishida T
    Am J Hematol; 1994 Apr; 45(4):298-303. PubMed ID: 8178801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of activated human protein C on disseminated intravascular coagulation induced by lipopolysaccharide in rats.
    Aoki Y; Ota M; Katsuura Y; Komoriya K; Nakagaki T
    Arzneimittelforschung; 2000 Sep; 50(9):809-15. PubMed ID: 11050697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of low molecular weight heparin (FR-860) on the experimental disseminated intravascular coagulation models].
    Hamano S; Kinukawa M; Komatsu H; Miyata H; Sakuragawa N
    Nihon Yakurigaku Zasshi; 1991 Jul; 98(1):53-62. PubMed ID: 1889762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplified anticoagulant activity of tissue factor-targeted thrombomodulin: in-vivo validation of a tissue factor-neutralizing antibody fused to soluble thrombomodulin.
    Wang YX; Wu C; Vincelette J; Martin-McNulty B; Alexander S; Larsen B; Light DR; McLean K
    Thromb Haemost; 2006 Sep; 96(3):317-24. PubMed ID: 16953273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis).
    Mohri M; Gonda Y; Oka M; Aoki Y; Gomi K; Kiyota T; Sugihara T; Yamamoto S; Ishida T; Maruyama I
    Blood Coagul Fibrinolysis; 1997 Jul; 8(5):274-83. PubMed ID: 9282791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The glycosaminoglycan of recombinant human soluble thrombomodulin affects antithrombotic activity in a rat model of tissue factor-induced disseminated intravascular coagulation.
    Nawa K; Itani T; Ono M; Sakano K; Marumoto Y; Iwamoto M
    Thromb Haemost; 1992 Mar; 67(3):366-70. PubMed ID: 1322570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human soluble thrombomodulin delivers bounded thrombin to antithrombin III: thrombomodulin associates with free thrombin and is recycled to activate protein c.
    Aritomi M; Watanabe N; Ohishi R; Gomi K; Kiyota T; Yamamoto S; Ishida T; Maruyama I
    Thromb Haemost; 1993 Sep; 70(3):418-22. PubMed ID: 8259541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroperative effects of fresh frozen plasma and antithrombin III on heparin sensitivity and coagulation during nitroglycerine infusion in coronary artery bypass surgery.
    Kanbak M; Oc B; Salman MA; Ocal T; Oc M
    Blood Coagul Fibrinolysis; 2011 Oct; 22(7):593-9. PubMed ID: 21799398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein C activation by recombinant thrombomodulin in plasma.
    Edano T; Komine N; Yoshizaki H; Ohkuchi M
    Biol Pharm Bull; 1998 Feb; 21(2):177-9. PubMed ID: 9514616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormalities of coagulation in experimental nephrotic syndrome.
    Cruz C; Juárez-Nicolás F; Tapia E; Correa-Rotter R; Pedraza-Chaverrí J
    Nephron; 1994; 68(4):489-96. PubMed ID: 7532794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin binding domain of antithrombin III: characterization using a synthetic peptide directed polyclonal antibody.
    Smith JW; Dey N; Knauer DJ
    Biochemistry; 1990 Sep; 29(38):8950-7. PubMed ID: 2271570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.